Press Release / Jan 25, 2019
Hovione issues $50 million bond
Hovione has issued a bond of $50 million US dollars maturing in 2033.
Press Room
Press Release / Oct 17, 2018
Hovione increases production capacity
‘One Site Shop’ expands to respond to growing demands
Press Release / Mar 19, 2018
Hovione reports on recent capacity expansion and future plans to support growth
Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey.
Press Release / Mar 08, 2018
Compliance at Hovione - Annual Inspection Review
Hovione announced today that in the last year their manufacturing facilities were the object of eight inspections, performed by different Health Authorities.
Press Release / Mar 07, 2018
Hovione sells the iMAX business
Hovione announces that it has concluded the sale of all of the share capital of iMAX Diagnostic Imaging limited.
Press Release / Jan 24, 2018
Hovione strengthens Inhalation Services portfolio
Hovione announced that a new MG2 Tekna Precision Capsule filling unit is now online in its Portugal facilities
Press Release / Dec 04, 2017
Hovione Announces Enrollment of First Patient in MARS
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Press Release / Sep 27, 2017
Hovione appoints Frédéric Kahn Vice President, Marketing and Sales
Hovione announced today the appointment of Mr. Frédéric Kahn as Vice President Marketing and Sales, as of 1st September, 2017
Press Release / May 25, 2017
Hovione Announces Start of Phase 1 Clinical Trial of HY02
HY02, a Proprietary Minocycline Sterile Ointment to Treat a Subset of Anterior Ocular Inflammation
Press Release / Jun 16, 2016
Hovione announces the groundbreaking expansion plans of its New Jersey Facility
Hovione announced today that it held on June 8th the official groundbreaking for the expansion of its New Jersey facility in East Windsor, USA
Contact Us
If you would like to learn more about Hovione, kindly fill in the form below and we will be revert to you soon.